{"context":{"query":">>mesh>>pharmgkb_clinical","source_dataset":"mesh","target_dataset":"pharmgkb_clinical"},"stats":{"queried":1,"total":10,"mapped":1},"pagination":{"has_next":false},"schema":"id|variant|gene|type|level_of_evidence|chemicals|phenotypes","mappings":[{"input":"D001281","source":"D001281|Atrial Fibrillation","targets":["CYP2C19*1__CYP2C19*2__CYP2C19*3_CYP2C19_9|CYP2C19*1, CYP2C19*2, CYP2C19*3|CYP2C19|Dosage|3|warfarin|Atrial Fibrillation","CYP2C9*1__CYP2C9*2__CYP2C9*3__CYP2C9*13__CYP2C9*14_CYP2C9_1|CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*13, CYP2C9*14|CYP2C9|Efficacy|2A|warfarin|Atrial Fibrillation;Heart valve replacement","RS1801253_ADRB1_8|rs1801253|ADRB1|Efficacy|4|atenolol|Atrial Fibrillation;Essential hypertension;Tachycardia","RS2108622_CYP4F2_2|rs2108622|CYP4F2|Dosage|2A|acenocoumarol|Atrial Fibrillation","RS2231142_ABCG2_13|rs2231142|ABCG2|Metabolism/PK|3|apixaban|Atrial Fibrillation","RS2244613_CES1_1|rs2244613|CES1|Toxicity|3|dabigatran|Atrial Fibrillation","RS2592551_GGCX_1|rs2592551|GGCX|Dosage|3|warfarin|Atrial Fibrillation","RS4148738_ABCB1_1|rs4148738|ABCB1|Metabolism/PK|3|dabigatran|Atrial Fibrillation","RS776746_CYP3A5_15|rs776746|CYP3A5|Metabolism/PK|3|apixaban|Atrial Fibrillation","RS8192935_CES1_1|rs8192935|CES1|Metabolism/PK|3|dabigatran|Atrial Fibrillation"]}]}